The Global Market for Nanobiotechnology is Projected to Reach US$39.4 Billion by 2022

Advancements in Nanomedicine Research Provides the Platform for Growth of Nanobiotechnology, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Nanobiotechnology market. The global market for Nanobiotechnology is projected to reach US$39.4 billion by 2022, driven by growing R&D efforts directed at enabling the development of diverse nanotech-based solutions in nanomedicine and other medical science fields.

Nanobiotechnology, a sub-segment of nanotechnology, is a combination of molecular engineering, chemistry, biotechnology, biology and physical sciences. By reapplying the success of nanotechnology into the field of biology, market participants are keen on crossing the threshold of this next frontier by developing tools to explore the proteins contained within a cell to architecture a communication channel between physical objects such as electronic devices, and living matter such as cells, and neurons. Nanobiotechnology is increasingly used in life sciences research, particularly in cell-level research which has the potential to enhance nanobiotechnology’s role in pharma and healthcare. Nanobiotechnology today stands optimally positioned to extend its clout into biotechnology (drug delivery, tissue engineering, drug discovery, diagnostics, implantable devices, and imaging agents), pharmacy, medicine, and health.

The technology is forecast to tailspin modern day healthcare by revolutionizing every facet of health, diagnostics, and treatment, by making it more efficient, focused, target-specific, and less invasive. Competitive strongpoints driving the success of nanobiotechnology include ability to control and manipulate nanoscale chemical and structural building blocks of life i.e. molecules; and rapid strides in nanoparticle synthesis. The technology is revered for its ability to open up new possibilities for intracellular drug delivery and fortify the ability of the medical community to battle against several fatal diseases such as cancer, AIDS, and various neurological and cardiovascular disorders. Factors such as increased research funding, transfer of technological know-how, continuously rising chronic diseases prevalence, and breakthrough developments that unlock the potential of nanomedicine for resolving some of the unmet needs in the medical field are other major growth drivers.

As stated by the new market research report on Nanobiotechnology, the United States represents the largest market worldwide. Rest of World comprising Asia-Pacific, Latin America, the Middle East, Africa and Canada constitutes the fastest growing market, flaunting a CAGR of 10.5% over the analysis period. Among the emerging regions, Asia-Pacific represents an important market driven by developments in the area of healthcare technologies and infrastructure, and increased acceptance of new treatment technologies. Latin America represents the other major market with several major companies like J&J and Novartis among others expanding their operations in Mexico, Brazil and other Latin American countries.

Leading players in the market include Ablynx NV, Arrowhead Pharmaceuticals Inc., CaPtivate Pharmaceuticals LLC, Celgene Corporation, ELITechGroup, Flamel Technologies SA, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., NanoBio® Corporation, Nanophase Technologies Corporation, pSivida Corp., Sigma-Aldrich Corp., Starpharma Holdings Ltd., and Vectura Group plc, among others.

The research report titled “Nanobiotechnology: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, innovations and strategic industry activities of major companies worldwide. The report provides market estimates and projections in value terms for all major geographic markets including the US, Japan, Europe and Rest of World.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.